Original Article

Management of Pulmonary Embolism: A Single-Center Experience

Authors: R. Holt Hammons, BS, Sibu P. Saha, MD, MBA

Abstract

Objective: Pulmonary embolism (PE) is the third leading cause of cardiovascular death. The objective of this study was to examine the current management of pulmonary embolism at a single academic institution.

Methods: With institutional review board approval, we conducted a retrospective chart review of 805 encounters among 775 patients presenting with acute PE from January 1, 2016 to June 30, 2019. We used American Heart Association guidelines for PE risk stratification.

Results: In total, 409 patients were given the low-risk designation, 377 of these patients (92%) were anticoagulated with heparin or enoxaparin, and 32 patients (8%) were given a direct oral anticoagulant alone. There were two in-hospital mortalities (0.5%) in the low-risk group; 322 patients were in the true intermediate-risk category (ie, did not progress to high risk), and 320 patients received anticoagulation with heparin or enoxaparin (99.4%). Seventy-three patients (22%) received catheter-directed thrombolysis. There were eight in-hospital mortalities (2.5%) among the intermediate-risk group; eight intermediate-risk patients progressed to high-risk during their hospital stay, resulting in 6 in-hospital mortalities (75%) in this group. There were 66 patients designated as high-risk upon presentation. Sixty patients (91%) received heparin for anticoagulation and 47 patients (71%) required advanced therapies. Fourteen high-risk patients (21%) had bleeding complications, and there were 26 (39%) in-hospital mortalities.

Conclusions: The management of PE has evolved, and proper risk stratification is key. Largely speaking, low- and intermediate-risk patients can be treated with anticoagulation, whereas patients with severe right ventricular strain and hemodynamic instability may require more advanced therapies.
Posted in: Cardiovascular Disease42

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Hountras P, Bull TM. Advanced therapies for pulmonary embolism. Curr Opin Pulm Med 2020;26:397-405.
 
2. Lewis AE, Gerstein NS, Venkataramani R, et al. Evolving management trends and outcomes in catheter management of acute pulmonary embolism. J Cardiothorac Vasc Anesth 2022; 36(8 Pt B):3344-3356.
 
3. Giri J, Sista AK, Weinberg I, et al. Interventional therapies for acute pulmonary embolism: current status and principles for the development of novel evidence: a Scientific Statement from the American Heart Association. Circulation 2019;140:e774-e801.
 
4. Dalen JE, Alpert JS. Diagnosis and treatment of pulmonary embolism: what have we learned in the last 50 years? Am J Med 2020;133:404-406.
 
5. Martin C, Sobolewski K, Bridgeman P, et al. Systemic thrombolysis for pulmonary embolism: areview.PT2016;41:770-775.
 
6. Leidi A, Bex S, Righini M, et al. Risk stratification in patients with acute pulmonary embolism: current evidence and perspectives. JClinMed2022;11:2533.
 
7. George B, Parazino M, Omar HR, et al. A retrospective comparison of survivors and nonsurvivors of massive pulmonary embolism receiving veno-arterial extracorporeal membrane oxygenation support. Resuscitation 2018;122:1-5.
 
8. Licha CRM, McCurdy CM, Maldonado SM, etal. Current management of acute pulmonary embolism. Ann Thorac Cardiovasc Surg 2020;26:65-71.
 
9. Chen YL, Wright C, Pietropaoli AP, et al. Right ventricular dysfunction is superior and sufficient for risk stratification by a pulmonary embolism response team. J Thromb Thrombolysis 2020;49:34-41.
 
10. Kabrhel C, Rosovsky R, Channick R, et al. A multidisciplinary pulmonary embolism response team: initial 30-month experience with a novel approach to delivery of care to patients with submassive and massive pulmonary embolism. Chest 2016;150:384-393.
 
11. Rosovsky R, Chang Y, Rosenfield K, et al. Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year analysis. J Thromb Thrombolysis 2019;47:31-40.
 
12. Duffett L, Castellucci LA, Forgie MA. Pulmonary embolism: update on management and controversies. BMJ 2020;370:m2177.
 
13. Freund Y, Cohen-Aubart F, Bloom B. Acute pulmonary embolism: a review. JAMA 2022;328: 1336-1345.
 
14. Sedhom R, Megaly M, Elbadawi A, et al. Contemporary national trends and outcomes of pulmonary embolism in the United States. Am J Cardiol 2022;176:132-138.
 
15. Oh YN, Oh DK, Koh Y, et al. Use of extracorporeal membrane oxygenation in patients with acute high-risk pulmonary embolism: a case series with literature review. Acute Crit Care 2019;34:148-154.
 
16. Kmiec L, Philipp A, Floerchinger B,et al. Extra corporeal membrane oxygenation for massive pulmonary embolism as bridge to therapy. ASAIO J 2020;66:146-152.
 
17. Kay DF, Madjarov JM, Tenny BC. Case report: re-emerging significance of surgical embolectomy in pulmonary embolism. Ann Med Surg 2019;39:26-28.
 
18. Jaff MR, McMurtry MS, Archer SL, et al; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a Scientific Statement from the American Heart Association. Circulation 2011;123:1788-1830.
 
19. Pollack CV, Schreiber D, Goldhaber SZ, et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol 2011;57:700-706.
 
20. Naoum JJ. Anticoagulation management post pulmonary embolism. Methodist Debakey Cardiovasc J 2024;20(3):27–35.
 
21. Chopard R, Campia U, Morin L, et al. Trends in management and outcomes of pulmonary embolism with a multidisciplinary response team. J Thromb Thrombolysis 2022;54:449–460.
 
22. Rivera-Lebron B, McDaniel M, Ahrar K, et al. Diagnosis, treatment and follow up of acute pulmonary embolism: consensus practice from the PERT Consortium. Clin Appl Thromb Hemost 2019;25:1076029619853037.
 
23. Jiménez D, de Miguel-Díez J, Guijarro R, et al. Trends in the management and outcomes of acute pulmonary embolism: analysis From the RIETE Registry. J Am Coll Cardiol 2016;67: 162-170.
 
24. Yusuff HO, Zochios V, Vuylsteke A. Extracorporeal membrane oxygenation in acute massive pulmonary embolism: a systematic review. Perfusion 2015;30:611-616.
 
25. Ebner M, Kresoja KP, Keller K, et al. Temporal trends in management and outcome of pulmonary embolism: a single-centre experience. Clin Res Cardiol 2020;109:67-77.
 
26. Kujovich JL, Factor V. Leiden thrombophilia. Genet Med 2011;13:1-16.